A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition

Lars M. Schiffmann(University of Cologne), Oliver Coutelle(University of Cologne)
British Journal of Cancer
January 31, 2017
Cited by 37


Related Papers